$BEAT News Article Out: HeartBeam strengthens IP with US patents for cardiac monitoring
Medical Device Network-Global Data
Wed, May 7, 2025 at 10:10 AM EDT
In This Article:
BEAT, BEATW
HeartBeam has secured two new US patents, strengthening its intellectual property (IP) portfolio in cardiac monitoring technology.
The first patent pertains to the company’s cable-free three-dimensional (3D) electrocardiogram (ECG) device, which is roughly the size of a credit card.
The device has been tailored for convenience, incorporating chest and finger electrodes to capture high-fidelity electrical signals from three non-coplanar directions.
Individuals can use the device to record symptoms as they occur, regardless of their location.
The captured signals are synthesised into a 12-lead ECG through a personalised transformational matrix.
HeartBeam's 12-lead ECG synthesis software is undergoing US Food and Drug Administration (FDA) review.
The VALID-ECG pivotal study, which assessed the ECG in non-life-threatening arrhythmias, confirmed that the device met its clinical endpoints.
The second patent secures the company’s rhythm analysis algorithm, which can identify arrhythmias such as atrial fibrillation and sinus rhythm from continuous signal input.
It can be integrated into any cardiac monitoring system, including wearables, and facilitates risk-based escalation by identifying anomalies during passive monitoring.
The algorithm can prompt users to gather 3D ECG signals with the company’s device for a 12-lead ECG.
The company's portfolio now includes 20 issued patents across the US and internationally, two allowed and 32 pending patents.
HeartBeam CEO Robert Eno stated: “HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility.
“The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care.”
HeartBeam recently entered a partnership with AccurKardia, a company specialising in ECG-based diagnostics software, to enhance the accessibility of cardiac monitoring solutions.
In December 2024, HeartBeam's 3D ECG technology was granted FDA clearance for arrhythmia assessment.
"HeartBeam strengthens IP with US patents for cardiac monitoring" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Link: https://finance.yahoo.com/news/heartbeam-stre...14886.html
Medical Device Network-Global Data
Wed, May 7, 2025 at 10:10 AM EDT
In This Article:
BEAT, BEATW
HeartBeam has secured two new US patents, strengthening its intellectual property (IP) portfolio in cardiac monitoring technology.
The first patent pertains to the company’s cable-free three-dimensional (3D) electrocardiogram (ECG) device, which is roughly the size of a credit card.
The device has been tailored for convenience, incorporating chest and finger electrodes to capture high-fidelity electrical signals from three non-coplanar directions.
Individuals can use the device to record symptoms as they occur, regardless of their location.
The captured signals are synthesised into a 12-lead ECG through a personalised transformational matrix.
HeartBeam's 12-lead ECG synthesis software is undergoing US Food and Drug Administration (FDA) review.
The VALID-ECG pivotal study, which assessed the ECG in non-life-threatening arrhythmias, confirmed that the device met its clinical endpoints.
The second patent secures the company’s rhythm analysis algorithm, which can identify arrhythmias such as atrial fibrillation and sinus rhythm from continuous signal input.
It can be integrated into any cardiac monitoring system, including wearables, and facilitates risk-based escalation by identifying anomalies during passive monitoring.
The algorithm can prompt users to gather 3D ECG signals with the company’s device for a 12-lead ECG.
The company's portfolio now includes 20 issued patents across the US and internationally, two allowed and 32 pending patents.
HeartBeam CEO Robert Eno stated: “HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility.
“The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care.”
HeartBeam recently entered a partnership with AccurKardia, a company specialising in ECG-based diagnostics software, to enhance the accessibility of cardiac monitoring solutions.
In December 2024, HeartBeam's 3D ECG technology was granted FDA clearance for arrhythmia assessment.
"HeartBeam strengthens IP with US patents for cardiac monitoring" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Link: https://finance.yahoo.com/news/heartbeam-stre...14886.html
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
